BA
ZYNE

BlackRock Advisors’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

BlackRock Advisors’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-873
Closed -$8K – 3821
2016
Q1 		$8K Hold
873
– – ﹤0.01% 3611
2015
Q4 		$9K Sell
873
-756
-46% -$10K ﹤0.01% 3646
2015
Q3 		$23K Buy
+1,629
New +$40K ﹤0.01% 3485

Other funds holding ZYNE

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
AAM
Auxier Asset Management Aurora, Oregon $745M AUM 27.52% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
AGM
Alpine Global Management New York $615M AUM 34.28% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

BlackRock Advisors's ZYNE Position: Q2 2016 in Review

BlackRock Advisors sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q2 2016, closing a stake of 873 shares — an estimated $8K sold.

BlackRock Advisors first reported a position in ZYNE in Q3 2015 and held it in 3 quarters. The position peaked at $23K in Q3 2015. 26 funds tracked by Wall St. Rank hold ZYNE as of Q2 2016.

  • BlackRock Advisors reported no remaining Zynerba Pharmaceuticals, Inc position as of Q2 2016 after selling out during the quarter.
  • BlackRock Advisors sold 873 Zynerba Pharmaceuticals, Inc shares in Q2 2016, an estimated $8K.
  • BlackRock Advisors first reported a position in Zynerba Pharmaceuticals, Inc in Q3 2015 and held it in 3 quarters.
  • BlackRock Advisors's Zynerba Pharmaceuticals, Inc position peaked at $23K in Q3 2015.
  • 26 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q2 2016.

Based on BlackRock Advisors's 13F filing for Q2 2016, filed 10 Aug 2016.